论文部分内容阅读
Phase Ⅲ, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus
【作 者】
：
【机 构】
：
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
【出 处】
：
2015年临床肿瘤学新进展学术研讨会
【发表日期】
：
2015年3期
其他文献
A randomized phase Ⅱ study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimu
会议
Docetaxel and/or zoledronic acid for hormone-na(i)ve prostate cancer: First overall survival results
会议
Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respo
会议
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or re
会议
CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN a
会议
会议
Results of a first-in-human, phase Ⅰ/Ⅱ trial of ASP2215, a selective, potent inhibitor of FLT3/Axl i
会议
Results of the PERSIST-1 phase Ⅲ study of pacritinib (PAC) versus best available therapy (BAT) in pr
会议